AccuLine
Preventing the next Heart Attack
Company Overview
Snapshot
Founded in February 2022 by Moshe Barel, Aaron Frimerman, and Shai Revzen, AccuLine operates with 11–50 employees. The company has raised $6.25 million across five funding rounds from four investors. In September 2023, AccuLine announced a know-how license agreement with Mayo Clinic to advance the early detection of heart attacks.
Business overview
AccuLine is a Health Tech & Life Sciences company focused on preventing heart attacks through early detection of Coronary Artery Disease (CAD). The company develops CORA, a non-invasive, swift, and cost-effective examination system designed to replace traditional stress tests. CORA analyzes three vital signs—heart's electrical activity, oxygen saturation, and respiratory phase—to automatically generate results. AccuLine operates in the Digital Medical Diagnostics sector, leveraging artificial intelligence and machine learning to serve the healthcare industry, particularly providers, in North America.
Strategic signal
In July 2024, AccuLine secured a $4.2 million Seed round, indicating strong investor confidence in its non-invasive heart attack detection technology. This funding will likely accelerate the development and clinical validation of its CORA system, positioning AccuLine to potentially disrupt the cardiovascular diagnostics market with a more efficient and accessible solution for early CAD detection.
Company Intelligence Q&A
- What is AccuLine's primary mission?
- AccuLine's primary mission is to save lives by preventing heart attacks through the early detection of Coronary Artery Disease (CAD) using its non-invasive CORA examination system.
- What significant partnership did AccuLine announce in 2023?
- In September 2023, AccuLine announced a know-how license agreement with Mayo Clinic to further advance the early detection of heart attacks.
- What was a key financial milestone for AccuLine in 2024?
- In July 2024, AccuLine raised a $4.2 million Seed funding round to support its efforts in developing technology for early heart attack detection.
- Which organizations have provided grants to AccuLine?
- AccuLine has received grants from Google and the Israel Innovation Authority in May 2024, supporting its development efforts.
- Who are some of the notable investors in AccuLine?
- AccuLine's investors include eHealth Ventures and Maccabi Healthcare Services